Completed PHASE2 INTERVENTIONAL NCT00153010

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Sponsor: Boehringer Ingelheim

Conditions Alzheimer Disease

Interventions NS 2330 (Tesofensine)

Updated 6 times since 2017 Last updated: Oct 28, 2013 Started: Feb 28, 2003 Primary completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Amherst, United States , Atlanta, United States , Beachwood, United States , Beaconsfield, Canada , Bennington, United States , Berkeley, United States , Boca Raton, United States , Charlottesville, United States and 68 more locations